1. Home
  2. HROW

as of 05-20-2026 3:55pm EST

$31.15
+$0.47
+1.53%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Founded: 1998 Country:
United States
United States
Employees: 373 City: NASHVILLE
Market Cap: 1.4B IPO Year: N/A
Target Price: $69.86 AVG Volume (30 days): 842.7K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $25.21 - $54.98 Next Earning Date: 05-11-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 31.62% Revenue Growth (next year): 50.77%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered HROW Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 71.35%
71.35%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: